3.48MMarket Cap-0.19P/E (TTM)
3.0400High2.7000Low20.07KVolume3.0400Open2.9400Pre Close56.48KTurnover2.21%Turnover RatioLossP/E (Static)1.27MShares9.400052wk High0.20P/B2.50MFloat Cap2.700052wk Low--Dividend TTM908.92KShs Float170.0000Historical High--Div YieldTTM11.57%Amplitude2.7000Historical Low2.8140Avg Price1Lot Size
Pasithea Therapeutics Stock Forum
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
54 seconds ago, 4:02 AM PST
Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule --
-- No dose-limiting toxicities (DLTs) observed to date --
-- No rash observed to date --
📊⚡️📊
Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules
No comment yet